Merrimack Pharmaceuticals Inc. (MACK) Identifies Heregulin As Patient Response Biomarker For MM-121 And Standard Of Care Therapy Across Multiple Cancers
6/2/2014 9:28:51 AM
CAMBRIDGE, Mass., June 2, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today reported that expression of heregulin (HRG), the principal ligand that binds to and activates the ErbB3 receptor, is associated with poor response to standard of care therapy for patients with platinum-resistant ovarian cancer, ER/PR+ HER2- breast cancer and EGFR wild-type non-small cell lung cancer. Heregulin-driven drug resistance pathways were found to be active in approximately 30-50 percent of patients tested.
Help employers find you! Check out all the jobs and post your resume.
comments powered by